Reuters logo
BRIEF-Alnylam Pharmaceuticals announces initial 2017 pipeline goals
December 16, 2016 / 12:33 PM / 9 months ago

BRIEF-Alnylam Pharmaceuticals announces initial 2017 pipeline goals

Dec 16 (Reuters) - Alnylam Pharmaceuticals Inc :

* Assuming positive phase 3 data, plans to submit nda for Patisiran at year-end 2017

* Company announces positive preliminary results from phase 1 study of ALN-TTRsc02

* 2017 pipeline goals includes the completion of APOLLO phase 3 study

* Co plans to initiate Atlas phase 3 program in early 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below